Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports
Upadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis. The current case report describes two UC patients with high...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-03-01
|
| Colecção: | Frontiers in Immunology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1716943/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|